Bose P - Search Results

1

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.

Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Saenz DT, et al. Among authors: bose p. Leukemia. 2019 Jun;33(6):1373-1386. doi: 10.1038/s41375-018-0334-3. Epub 2018 Dec 21. Leukemia. 2019. PMID: 30575820

2

The evolution and clinical relevance of prognostic classification systems in myelofibrosis.

Bose P, Verstovsek S. Bose P, et al. Cancer. 2016 Mar 1;122(5):681-92. doi: 10.1002/cncr.29842. Epub 2015 Dec 30. Cancer. 2016. PMID: 26717494 Free article. Review.

3

Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.

Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V. Cervantes-Gomez F, et al. Among authors: bose p. Leukemia. 2016 Aug;30(8):1803-4. doi: 10.1038/leu.2016.129. Epub 2016 May 20. Leukemia. 2016. PMID: 27198052 Free PMC article. No abstract available.

4

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Naqvi K, et al. Among authors: bose p. Leuk Lymphoma. 2017 Apr;58(4):866-871. doi: 10.1080/10428194.2016.1217528. Epub 2016 Aug 5. Leuk Lymphoma. 2017. PMID: 27494751 Free PMC article.

5

Prognosis of Primary Myelofibrosis in the Genomic Era.

Bose P, Verstovsek S. Bose P, et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S105-13. doi: 10.1016/j.clml.2016.02.031. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27521306 Free PMC article. Review.

6

Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.

Bose P, Verstovsek S. Bose P, et al. Expert Opin Investig Drugs. 2016 Dec;25(12):1393-1403. doi: 10.1080/13543784.2016.1250882. Epub 2016 Oct 31. Expert Opin Investig Drugs. 2016. PMID: 27756180 Free PMC article. Review.

7

Myelofibrosis: an update on drug therapy in 2016.

Bose P, Verstovsek S. Bose P, et al. Expert Opin Pharmacother. 2016 Dec;17(18):2375-2389. doi: 10.1080/14656566.2016.1252333. Epub 2016 Nov 7. Expert Opin Pharmacother. 2016. PMID: 27774820 Free PMC article. Review.

8

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.

Bose P, Verstovsek S. Bose P, et al. J Natl Compr Canc Netw. 2016 Dec;14(12):1613-1624. doi: 10.6004/jnccn.2016.0170. J Natl Compr Canc Netw. 2016. PMID: 27956543 Review.

9

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Falchi L, Bose P, Newberry KJ, Verstovsek S. Falchi L, et al. Among authors: bose p. Br J Haematol. 2017 Feb;176(3):352-364. doi: 10.1111/bjh.14443. Epub 2016 Dec 16. Br J Haematol. 2017. PMID: 27984634 Free article. Review.

10

Pathways and mechanisms of venetoclax resistance.

Bose P, Gandhi V, Konopleva M. Bose P, et al. Leuk Lymphoma. 2017 Sep;58(9):1-17. doi: 10.1080/10428194.2017.1283032. Epub 2017 Jan 31. Leuk Lymphoma. 2017. PMID: 28140720 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

607 results

Search Page